✦ LIBER ✦

[604] COMPARISON OF A SHORTENED RIBAVIRIN TREATMENT VS A 24 WEEK STANDARD COMBINATION THERAPY IN HCV INFECTED PATIENTS WITH GENOTYPE 2/3

✍ Scribed by B. Kallinowski; K. Stein; W. Boecher; T. Goeser; U. Spengler; R. Link; H. Klinker; T. Bruckner; P. Haiss; P. Buggisch

Book ID: 117375696
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 276 KB
Volume: 46
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(07)62202-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[606] COMPARISON OF PEGINTERFERON a-2a A

[606] COMPARISON OF PEGINTERFERON a-2a AND RIBAVIRIN FOR 12 OR 24 WEEKS IN PATIENTS WITH HCV GENOTYPE 2/3: THE NORDYNAMIC TRIAL

✍ M. Lagging; C. Pedersen; M. Rauning Buhl; M. Farkkila; N. Langeland; K. Morch; G 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Predicting treatment outcome following 2

Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6

✍ Esther Lukasiewicz; Kristoffer Hellstrand; Johan Westin; Carlo Ferrari; Avidan U 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

We sought to validate FIB-4 using data retrospectively collected from treatment-naive HIV/HCV patients. The original model was adapted in order to use AST and ALT levels expressed as times the upper limit of normality (ϫULN), as follows: (age [yr] ϫ AST [ϫULN]) ϫ 10/((PLT [10 9 /l]) ϫ (ALT [ϫULN]) 1

The results of a randomized trial lookin

The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon α-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1

✍ C. Brandão; A. Barone; F. Carrilho; A. Silva; M. Patelli; C. Caramori; R. Focacc 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

1418 DACLATASVIR COMBINED WITH PEGINTERF

1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY

✍ Dore, G.J.; Lawitz, E.; H'ezode, C.; Shafran, S.; Ramji, A.; Tatum, H.; Taliani, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 78 KB

O109 ALL ORAL FIXED-DOSE COMBINATION SOF

O109 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDY

✍ Afdhal, N.; Reddy, R.K.; Pockros, P.; Di Bisceglie, A.M.; Arora, S.; Yang, J.C.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 151 KB

2005 VIROLOGIC RESPONSE RATES FOLLOWING

2005 VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS

✍ Jacobson, I.; Pockros, P.J.; Lalezari, J.; Lawitz, E.; Rodriguez-Torres, M.; DeJ 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 51 KB